PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 10, 2026Cancer Immunology Immunotherapy0 citationsOpen Access

Novel Protein PK5-Gal-3C Enhances T Cell Anti-Tumor Activity via TRPV2 Binding

Novel recombinant protein PK5-Gal-3C enhances the anti-tumor activity of T cells via binding with TRPV2

View Full Paper

Authors

GZGuopeng ZhangWZWei ZhangXWXiaohuan Wei

Discussion

Loading...

Member takes

Overview

Randomized trial reveals enhanced T cell anti-tumor activity via TRPV2 binding, suggesting new immunotherapy options.

Key Points

  • The study aims to investigate the impact of the novel recombinant protein PK5-Gal-3C on T cell anti-tumor activity.
  • Developed the recombinant protein PK5-Gal-3C combining PK5 and Gal-3C domains.
  • Evaluated T cell activation and cytotoxicity in mouse models.
  • Assessed the anti-tumor efficacy of CAR-T cells in combination with PK5-Gal-3C.
  • PK5-Gal-3C significantly increased T cell cytotoxicity by enhancing calcium influx through TRPV2.
  • Inhibition of TRPV2 or c-Jun reduced T cell cytotoxicity mediated by PK5-Gal-3C.
  • Enhanced T cell infiltration and anti-tumor efficacy in solid tumor models.
Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/6a0021fec8f74e3340f9cf98https://doi.org/10.1007/s00262-026-04401-3
Ask AI
Helpful
Bookmark
Share
View Full Paper